Sequence: VQWRIRVAVIRRVVVSR + C12 fatty acid
| Experiment Id | EXP002190 |
|---|---|
| Paper | In silico optimized cell-penetrating peptides achieve transdermal siRNA delivery and regulate inflam |
| Peptide | LAU-DP7 |
| Delivery Success Class | no |
| In Vivo Flag | yes |
| Uptake Confirmed | no |
| Label Confidence | high |
| In Vitro Functional Effect | |
| Endosomal Escape Evidence | |
| Peptide Concentration | 30 µg per mouse |
| Rna Concentration | 10 µg per mouse |
| Mixing Ratio | 3:1 (peptide:siRNA, w/w) |
| Formulation Format | FA-DP7/siRNA@Gelatin spray |
| Formulation Components | FA-DP7 + siRNA + gelatin spray |
| Size Nm | |
| Zeta Mv | |
| Model Scope | in_vivo |
| Model Type | in vivo |
| Cell Lines Or Primary Cells | |
| Animal Model | IMQ-induced psoriasis mouse model |
| Administration Route | topical transdermal spray |
| Output Type | psoriasis severity, ADAM17 knockdown, cytokines |
| Output Value | PAL/STE significantly ameliorate psoriasis |
| Output Units | |
| Output Notes | PAL-DP7 and STE-DP7 achieved transdermal delivery and therapeutic effect |
| Toxicity Notes | No skin irritation or systemic toxicity |
| Curation Notes |